[HTML][HTML] Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly …
The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline
for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of …
for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of …
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
AB van der Aart-van der Beek, RA de Boer… - Nature Reviews …, 2022 - nature.com
Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …
availability of pharmacological treatments, both diseases remain associated with …
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update
L Blonde, GE Umpierrez, SS Reddy, JB McGill… - Endocrine Practice, 2022 - Elsevier
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
[HTML][HTML] Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
Abstract Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …
Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …
[HTML][HTML] Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression
JM Rodriguez-Valadez, M Tahsin… - Diabetes …, 2023 - Am Diabetes Assoc
BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …
[HTML][HTML] Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the …
OBJECTIVE These post hoc analyses of the Semaglutide Treatment Effect in People with
obesity (STEP) 1–3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the …
obesity (STEP) 1–3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the …
Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP/TAZ activation
L Feng, Y Chen, N Li, X Yang, L Zhou, H Li, T Wang… - Life Sciences, 2023 - Elsevier
In diabetic kidney disease (DKD), the long-term hyperactivation of yes-associated protein
(YAP)/transcriptional coactivator PDZ-binding motif (TAZ) in renal proximal tubule epithelial …
(YAP)/transcriptional coactivator PDZ-binding motif (TAZ) in renal proximal tubule epithelial …
The growing challenge of chronic kidney disease: an overview of current knowledge
R Borg, N Carlson, J Søndergaard… - International Journal of …, 2023 - Wiley Online Library
Chronic kidney disease (CKD) is becoming one of the world's most prevalent
noncommunicable chronic diseases. The World Health Organization projects CKD to …
noncommunicable chronic diseases. The World Health Organization projects CKD to …
Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment
VR Aroda, RH Eckel - Diabetes, Obesity and Metabolism, 2022 - Wiley Online Library
It is well known that the multiple factors contributing to the pathogenesis of type 2 diabetes
(T2D) confer an increased risk of developing cardiovascular disease (CVD). Although the …
(T2D) confer an increased risk of developing cardiovascular disease (CVD). Although the …
[PDF][PDF] Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
BACKGROUND: Chronic kidney disease (CKD) is associated with fluid excess which can be
estimated by bioimpedance spectroscopy. We aimed to assess effects of sodium glucose co …
estimated by bioimpedance spectroscopy. We aimed to assess effects of sodium glucose co …